858.277.5678
Quality Patient Care. Exceptional Research.
News

Abbvie releases first of six phase III results from investigational all-oral, interferon-free, 12- week regimen, showing 96% SVR12 in genotype 1 hepatitis C patients new to therapy

Download the PDF